Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // May 13th, 2010 // 6:14 am
Top of the morning to you. Another shiny day here on the Pharmalot corporate campus. What will today bring? We can only guess. But with meetings and deadlines on the agenda, we are brewing the required cups of stimulation. Meanwhile, here are a few interesting items to help you prepare. We hope your day is productive and pleasant. And as always, do stay in touch…
Walgreen’s Halts Sales Of OTC Gene Tests (Bloomberg News)
India & Brazil Complain To WTO About EU Seizures (Agence France Presse)
Merck To Create 150 Jobs In Ireland (RTE Business)
Glaxo Halts Platelet Drug Study Due To Clots (Reuters)
AstraZeneca Fights SMC Rejection Of Iressa (PharmaTimes)
CVS Caremark Taps A New CEO (Associated Press)
US Rx DataBase Takes Hold Slowly (Government Technology)
Merck & Sanofi Prepare To Shed Animal Assets (Reuters)
Australia Won’t Enact New Price Cuts Until 2014 (PharmaTimes)
Chinese Editor Removed For Vaccine Safety Story (Sydney Morning Herald)
NicOx Arthritis Drug Is Rejected By FDA Panel (Reuters)
New Alzheimer’s Theory Explains Drug Failures (Reuters)
Coffee pix thx to chichcacha flickr creative commons
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Alzheimers, Animal Health, AstraZeneca, Australia, CVS Caremark, Drug Prices, Frontline, GlaxoSmithKline, Ireland, Iressa, jobs, Larry Merlo, Livestock, Merck, Merck Sharp & Dohme, Merial, NicOx, Pets, Promacta, Rx Prices, Sanofi Aventis, Scottish Medicines Consortium